EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy

Fangni Chai, Pan Li, Xin Liu, Zhihui Zhou, Haiyan Ren iD

Journal of Molecular Cell Biology · 2024

DOI: 10.1093/jmcb/mjad070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Molecular Cell Biology, 2024. Verfasst von Fangni Chai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a significant member of the immune checkpoint, programmed cell death 1 ligand 1 (PD-L1) plays a critical role in cancer immune escape and has become an important target for cancer immunotherapy. Clinically approved drugs mainly target the extracellular domain of PD-L1. Recently, the small cytoplasmic domain of PD-L1 has been reported to regulate PD-L1 stability and function through multiple pathways. Therefore, the intracellular domain of PD-L1 and its regulatory pathways could be promising targets for cancer therapy, expanding available strategies for combined immunotherapy. Here, we summarize the emerging roles of the PD-L1 cytoplasmic domain and its regulatory pathways. The conserved motifs, homodimerization, and posttranslational modifications of the PD-L1 cytoplasmic domain have been reported to regulate the membrane anchoring, degradation, nuclear translocation, and glycosylation of PD-L1. This summary provides a comprehensive understanding of the functions of the PD-L1 cytoplasmic domain and evaluates the broad prospects for targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsImmunotherapyHumansAnimalsProtein DomainsCytoplasmSignal TransductionProtein Processing, Post-Translational

Stichwörter der Autor:innen

PD-L1cytoplasmic domainimmunotherapyposttranslational modification

Substanzen

B7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Division of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
  • Collaborative Innovation Center of Biotherapy, Chengdu 610041, China.

ORCID-Profile: Haiyan Ren

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • West China Hospital, Sichuan University

Zitieren

APA

Chai, F., Li, P., Liu, X., Zhou, Z., & Ren, H. (2024). Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy. Journal of Molecular Cell Biology. https://doi.org/10.1093/jmcb/mjad070

Vancouver

Chai F, Li P, Liu X, Zhou Z, Ren H. Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy. Journal of Molecular Cell Biology. 2024. doi:10.1093/jmcb/mjad070

BibTeX
@article{Chai2024,
  author = {Chai, Fangni and Li, Pan and Liu, Xin and Zhou, Zhihui and Ren, Haiyan},
  title = {Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy},
  journal = {Journal of Molecular Cell Biology},
  year = {2024},
  doi = {10.1093/jmcb/mjad070}
}
Kostenlos starten →